UTILIZING A HALOHYDROCARBON CONTAINING DISSOLVED WATER TO INACTIVATE A LIPID VIRUS

Abstract: A method of inactivating a lipid virus contained in a dry protein carrier by contacting said virus-containing protein carrier for an abbreviated period of time at from 4-40<o>C. with a composition including a halohydrocarbon treating agent and water dissolved in said treating agent. Preferred lipid viruses are Hepatitus B virus (HBV) and non-A, non-B Hepatitus (NANBH) virus.

Description: UTILIZING A HALOHYDROCARBON CONTAINING DISSOLVED WATER TO INACTIVATE A LIPID VIRUS This invention relates to a method of inactivating a lipid virus contained in a dry protein carrier by contact¬ ing said virus-containing protein carrier for an extended period of time and ambient temperature with a halohydro- carbon solvent or treating agent, preferably chloroform, which contains dissolved water in an. amount between 75% and 100% of that amount required to saturate the solvent at the ambient temperature. Preferred viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH) virus. GENERAL BACKGROUND A selected lipid type virus, viral hepatitis, has been recognized as an important and serious sequela of parenteral exposure to blood and blood components since the early 1940s. It was originally believed that all such blood-associated hepatitis was caused by the serum hepatitis virus (now called the Hepatitis B virus, or HBV) . Subse¬ quently, the development of sensitive assays for infection with this virus revealed that only approximately one-third of transfusion-associated hepatitis was caused by the HBV. It was thought that the remaining hepatitis was caused by the Hepatitis A virus (HAV) . However, the development of sensitive assays for HAV led to the recognition of a new hepatitis virus, the non-A, non-B hepatitis virus (NANB) in 1975. The successful application of sensitive screening tests for HBV to blood donors has resulted in a decrease (but not disappearance) of HBV in transfusion-associated hepatitis; at present approximately 90% of such hepatitis is caused by non-A, non-B agents. Similarly, hepatitis following administration of plasma protein derivatives such as antihemophilic factor was thought to be caused solely by HBV. However, in the late 1970s, the association of NANB agents with adminis¬ tration of antihemophilic factor to hemophiliacs was re¬ ported and confirmed. As with transfusion-associated hepatitis, the application of serologic screening methods to plasma donors has resulted in a relative decrease in the importance of HBV in such blood product-associated hepatitis. Non-A, non-B hepatitis is the major cause of transfusion associated hepatitis in the United States. Prensently, less than 10% of post-transfusion causes are caused by the hepatitis B virus. Of the remainder, cyto- megalovirus may account for a small proportion but the vast majority are cuased by an as yet unidentified agent. There is a large amount of evidence supporting a trans¬ missible agent as the cause of NANBH. This includes trans¬ mission studies done in both humans and non-human primates. Chimpanzees and marmoset monkeys have both been shown to be susceptible to infection by at least some NANBH agents. Though very costly and cumbersome to work with, these animals can be used to aid in the characterization of the infectious agent of NANBH. Unfortunately, serologic tests for the detection of NANB agents are not available for detection and poten¬ tially infectious donors because the agents have not been adequately identified and characterized despite extensive efforts to do so. Therefore, blood and plasma protein de¬ rivative products remain potential sources for transmission of hepatitis agents to recipients. The resultant hepatitis can be quite serious, even life-threatening, and can result in not only acute hepatitis but also chronic hepatitis in a significant proportion of cases. For these reasons, attempts to inactivate hepa¬ titis agents in blood and plasma products have been pursued with vigor. Such approaches have included the use of heat, the addition of anti-HBV antibody, the use of solid immuno- adsorbents or other chemical-specific adsorbents, exposure to ultraviolet radiation, the addition of certain inacti¬ vating substances, such as beta-propriolactone, surface- active substances, etc. None of the approaches has been entirely successful and some have introduced an added potential risk (e.g., beta-propriolactone is carcinogenic). Failure of these approaches stems from relative resistance of the agents to physical or chemical inactivation, par¬ ticularly when in the presence of high protein concentra¬ tions as occurs with blood products and from limited know¬ ledge about the nature of the hepatitis agents, especially the NANB agents. As part of a systematic characterization of NANB agents by standardized virologic methods, the present in¬ ventors first established that HBV and at least one NANB agent contain lipids essential for the integrity and via¬ bility of the viruses. This was established by exposing the viruses to a potent lipid solvent (chloroform) and demon¬ strating that such chloroform-extracted viruses were rendered non-infectious in a suitable susceptible host, the chim¬ panzee (Pan troglodytes) . It was .later found that when viruses were con¬ tained in a dried protein carrier such as a commercial factor VIII concentrate preparation, the viruses were much more difficult to inactivate with the lipid solvent than when the protein carrier was reconstituted to a liquid with water and then treated with the lipid solvent. It was also found that the biologic activity of the protein carrier was difficult to maintain when it was treated as a liquid with the lipid solvent. Thus, this invention expands the parent invention by modifying the process in such a way that a lipid virus contained in a dry protein carrier, in particular a plasma derivative, can be readily and consistenly inactivated by a lipid solvent while the biologic activity of the plasma product is maintained at a high level. The present invention relates to a method of inactivating lipid viruses that frequently contaminate a plasma protein product. Said viruses are most frequently hepatitis B virus and non-A, non-B hepatitis virus but are also defined to include members of the herpesvirus group (cytomegalovirus, Epstein-Barr virus, herpes zoster virus, herpesvirus type 1 and type 2) , the delta agent (a type of non-A, non-B hepatitis virus) , togaviruses (including rubella virus) , bunya viruses, retroviruses (.including the human T-cell leukemia viruses) , orthomyxovi uses (in¬ cluding influenza) , paramyxoviruses (measles, mumps) , rhabdoviruses (rabies, Marburg agent) , arenaviruses (Lassa fever, other hemorrhagic fevers), coronaviruses, hepadna- viruses, and poxvirus group (smallpox, vaccinia virus). Other viruses, known or suspected, such as the putative agent of acquired immune deficiency syndrome (AIDS) are included as viruses possibly containing essential lipids. (Evidence that the agent of AIDS is a retrovirus has re¬ cently been published.) The plasma protein product is defined as a pro¬ tein derived from blood or blood plasma that is intended for human medical uses most often to correct a deficiency of that particular blood protein, or as an aid to treating some disease that might benefit from an increased concen¬ tration of the particular blood protein. Over 100 such plasma proteins have been identified and perhaps many more will eventually be found (cf. Putnam, Plasma Proteins, pp. 36-41 and Table 1) . Examples of such blood products are antihemophilic factor (factor VIII) , factor IX, fibrinogen, fibronectin, albumin, complement components, plasminogen, transferrin, and haptoglobin, and many other plasma pro¬ teins that have indicated medical uses but that may not at this time be marketed. In general, lipoproteins would not survive the process of this invention in their native state. In addition, certain blood proteins that are not intended for therapeutic use but may be used, for example, in diagnostic tests, may also be treated to reduce their hazard to the person handling them. Such plasma protein products are often dried by lyophilization during the manu- facture process in order to preserve their biologic potency, increase shelf life and. for ease of handling and shipping. The residual moisture content of such dried products ranges between about .5 and 1.5%. In the present invention the contaminating lipid containing viruses are inactivated by treating (extract¬ ing or contacting) the dry plasma product with a lipid solvent in which water has been dissolved such that the lipid solvent contains between about 75% to 100% of the amount of water required to reach its dissolved water sat¬ uration point. The preferred lipid solvent is chloroform (CHCln) or CHC1-. and a lower alcohol (e.g., methanol or ethanol) , or the fluorocarbons (trichlorotrifluoroethane) which include the most common agents such as CC1-F, CH ^ F-, CC1-.F.,, CC1-.FCC1F,. and others sold under the trademark registration Freon^or Genetron**. Throughout the present invention the biologic activity of the plasma protein is retained but the infectivity of the virus is removed. The period of time for the treatment is about 10 minutes to about 10 hours and at least about 10 minutes. The temperature of the treatment is from about 4°C. to 40°C. The quantity of lipid solvent used to treat dried plasma product is from about equal to the weight of the dry blood product to about 1,000 times the weight of the dry blood product. The lipid solvent or the treating agent may be removed from the plasma product by evaporation with a stream of pure, dry nitrogen gas (N~) , by vacuum evapora¬ tion or by a combination of these or other physical methods which returns the plasma product to the dry state and free of the lipid solvent. Commercial chloroform contains 0.5% (v/v) ethanol as a stabilizer. The quantity of dissolved water required to saturate pure chloroform varies between 0.019% (wt/v) at 3°C to 0.065% at 22°C to 0.118% at 43°C. (Stephen and Stephen (eds.) , Solubilities of Inorganic and Organic Compounds, Vol. 1, MacMillan Co., New York 1963, p. 370). Therefore, the absolute quantity of water in the chloroform can be increased by increasing the temperature. In addition, the quantity of dissolved water can be increased by in¬ creasing the ethanol concentration. It has been found that dry (water-free) chloro¬ form is inconsistently effective in inactivating vaccinia virus. It is believed that increases in the dissolved water content of the treating agent tend to increase the effec¬ tiveness of the inactivation treatment, with superior re¬ sults achieved as the water dissolved in the treating agent approaches 100% saturation of the treating agent at the temperature of treatment. It is believed that inactivation treatments should be conducted at saturation levels of from about 75 to about 100%. A two-phase system including water and treating agent, while relatively effective in inactiva¬ ting virus, may destroy activity of blood products, such as Factor VIII. MATERIAL INFORMATION DISCLOSURE A review of " the prior art of patents is as follows: US 4,113,712 Funakoshi - Utilization of a sur¬ factant such as the Tritons or Tweens for hepatitis B surface antigen particles. US 4,139,630 Asculai et al. - Utilization of non-ionic surfactants as inactivating agents for herpes simplex virus. US 4,314,997 Shanbrom - a non-denaturing amphi- phile used to inactivate hepatitis viruses B and non-A, non-B in amount of 0.25-10% by weight and citing non- anionic, anionic, and cationic surfactants. US 3,847,737 Kanarek - A method of inactivating myxoviruses by utilizing a treating composition consisting of Tween 20, 40, 60 or 80, e.g., a polyoxyethylene ester of partial oleic acid together with an organic solvent consisting of a chlorinated lower hydrocarbon having 2-5 carbon atoms. US 4,315,919 Shanbro - Similar disclosure to 4,314,997 above. US 4,031,204 Davis - This patent notes at column 4 that a 50% chloroform concentration will inactivate totally the feline viral rhinotracheitis (FVR ) virus. US 4,302,444 Baxendale - This patent indicates that for a vaccine for protecting against egg drop disease, the inactivation can be carried out with formaldehyde, with organic solvents, particularly halogenated hydrocarbons in the presence of a surface active agent, such as a polyoxy ethylene sorbitan mono-oleate or with beta-propriolactone. Non-patent literature is as follows: Purcell, "The Hepatitis Viruses: An Overview and Historical Perspective," Viral Hepatitis, 1981, Inter¬ national Symposium, Szmuness, Alter and Maynard (eds.), Franklin Institute Press, Philadelphia, pp. 3-12. Philipson, "Water-Organic Solvent Phase Systems." Methods in Virology, Maramorosch et al. (eds.), Vol. II, 1967, pp. 235-244. Feinstone et al., "Inactivation of Hepatitis B virus and Non-A, Non-B Hepatitis by Chloroform," Infec¬ tion and Immunity, Vol. 41, August 1983, pp. 816-821. EXAMPLE 1 Vaccinia virus, a member of the pox virus group was used as an example of lipid-containing viruses. The pox viruses are known to be the most difficult group of lipid-containing viruses to inactivate by lipid solvents. A sealed ampoule of lyophilized vaccinia virus, Elstree Strain ATCC #VR-862, was obtained from the American Type Culture Collection. The dry contents of the single ampoule were removed, divided into four approximately equal parts and placed into pre-weighed vials. The vials were then re-weighed to determine the weight of the dry powder containing- the vaccinia virus. The vials were num¬ bered 1, 2, 3 and 4 and they were then treated as follows: Vial #1 - 1 ml of chloroform from a freshly opened bottle (J.T. Baker Chemical #9180-1) . Vial #2 - 1 ml of chloroform (from an identical bottle) that had been saturated with water by shaking it for four hours with water; then allowing the phases to separate upon standing overnight. Vial #3 - 0.34 ml H 2 0 (0.236 ml H 2 0/mg of vac¬ cinia powder) was added to dissolve the vaccinia powder; then 0.66 ml fresh chloroform was added. Vial #4 - 0.446 ml H-,0 (0.236 ml/mg vaccinia powder) was added to dissolve the vaccinia powder. All vials were then placed on a rotary shaker and were shaken vigorously for four hours at room temper¬ ature (approximately 20°C) . The chloroform in vials #1 and #2 was evaporated off by a stream of purified, dry N ? gas. The aqueous (upper) phase was pipetted off the chloroform in vial #3. Vial #4 was not further treated. All vials were stored at -70°C until infectivity testing was performed. The amount of infectious vaccinia virus remain¬ ing after the various treatments was assayed by tissue cul¬ ture infectivity using BSC-1 cells. Quadruplicate wells of 24-well tissue culture plates containing monolayers of BSC-1 cells were inoculated with serial 10-fold dilutions of the vaccinia virus suspensions after they were treated. The BSC-1 cells were examined microscopically for the typ¬ ical cytopathic effect produced by vaccinia virus. Factor VIII concentrate (Koate, Cutter Labora¬ tories) was treated in a way similar to the vaccinia virus in order to test for retention of Factor VIII activity following extraction by chloroform. Factor VIII activity was determined by a commercial laboratory using standard techniques. Results The results are summarized in the following table Sample Treatment Vaccinia Titer Factor VIII No. (TCID 5( . Retention * (% of control) 1 Dry chloroform 10 5 75.6 2 H 2 0 Sat CHC1 3 ιo 0 - 5 75.6 3 H 2 0 + CHC1 3 10 1.25 15.0 (2 phase; 4 H 2 0 only 10 5.25 100.0 (control) * Compared to non-chloroform treated control (sample #4) Interpretation The dry chloroform was not effective in inacti¬ vating the dry vaccinia virus. The two-phase system and the water saturated CHC1., were effective inactivators of vaccinia. However, the two-phase (aqueous and CHC1. sys- stem also destroyed approximately 85% of the Factor VIII activity. Treatment of dry factor VIII with either the dry CHC1 3 or the water saturated CHC1 3 resulted in a re¬ tention of 75% of the Factor VIII activity. Thus, it was shown that vaccinia virus in the lyophilized state could be readily inactivated by chloro¬ form if the chloroform was first saturated with water. The pox virus group, of which vaccinia virus is a member, is known to be the group of viruses containing essential lipids that is the most difficult to inactivate by lipid solvents such as chloroform. Therefore, it can be reasoned that other viruses that contain essential lipids will also be readily inactivated in the dry state by the process of extracting them with chloroform that has been saturated in dissolved water. EXAMPLE 2 The purpose of this experiment was to determine the degree of H-^O saturation of the chloroform required to effectively kill viruses contained in a dry powder. Vac¬ cinia virus and Factor VIII concentrate were treated in SHEET various ways similar to the methodology of Example 1. The treatments were as follows: 1) CHC1 3 100% saturated by water ' 2) CHC1 3 75% saturated by water 3) CHC1 3 50% saturated by water 4) CHC1 3 25% saturated by water 5) CHC1 3 fresh, dry from a newly opened bottle of the same lot # as in 1-4 6) Fresh dry CHC1 3 + water in a two-phase system 7) Water only The CHC1-, that contained water at less than the saturation level was prepared by mixing appropriate volumes of 100% water-saturated CHC1 3 with dry CHC1 3 from a freshly opened bottle. In this way the desired saturation percent was easily achieved. Vials containing the dry vaccinia powder or the Factor VIII concentrate powder and the appro¬ priate treating agent were shaken vigorously on a rotary shaker at room temperature (approximately 20°C) for 4 hours. The CHC1., was evaporated off by a stream of nitrogen gas or the aqueous phase was separated from the CHC1-, by centri- fuging at 1000 RPM for 10 minutes and the aqueous phase (top layer) was carefully pipetted off. The redried pow¬ ders were reconstituted with a measured amount of water so that 0.2 ml of water was added per mg of vaccinia pow¬ der. The samples were then stored forzen at -70°C until testing. Vaccinia and Factor VIII were tested as described in Example 1. Results Vaccinia Factor VIII Titer Level Treatment (TCID 5Q ) (% of Control) 100% H 2 0 saturated CHC1 3 ιo 2 - 25 105% 75% " " " ιo 4 - 75 100 50% ιo 4 - 25 100 10 4.75 25% 110 Results. Vaccinia Factor III Titer Level (TCID 50 ) (% of Control) Dry fresh CHCl 3 10 4 110 H H 22 00++CCHHCC11 3 - (2 phase). 14 Interpretation Essentially 100% of the vaccinia virus was killed in the two-phase system but 80% of the Factor VIII was destroyed. ■ With 100% H 0 saturated CHCl greater than 99% -• • 3 of the vaccinia was killed and there was complete reten¬ tion of all Factor VIII activity compared to the control. However, when the content of the dissolved water was re¬ duced to 75% or less of the saturation level, there was essentially no virus killing although the Factor VIII ac¬ tivity was maintained. It must be concluded that greater than 75% of the water saturation level of CHC1 3 must be achieved in order to effectively kill the virus in the dry state. EXAMPLE 3 The purpose of this experiment was to test if increasing the H-,0 content of the chloroform treating agent would improve virus killing. This was accomplished by saturating the chloroform with water at a higher tem¬ perature (37°) which increases the amount of water that can be dissolved in the chloroform before saturation is achieved. The treatment was- also performed at 37°. The second method used to increase the water content was to increase the ethanol content of the chloro¬ form. Commercial chloroform contains about 0.5% (v/v) ethanol as a preservative. The water content of the chloro¬ form can be increased by increasing the ethanol content of the chloroform. In this experiment the ethanol content was increased from 0.5% to 2% and 5% and then the chloro- form/ethanol was saturated with water. The treatment pro¬ tocol was similar to those in Examples 1 and 2 in which weighed, lyophylized vaccinia powder and weighed, lyophy- lized Factor VIII concentrate were treated with the various chloroform preparations or water only as a control. Treat¬ ment was for 4 hours at the temperature stated in the pro¬ tocol. Chloroform was removed by evaporation with a stream of pure, dry nitrogen gas or in the case of water/chloro¬ form two-phase systems by contrifuging at 1000 RPM for 10 minutes and then pipetting off the aqueous phase. Dried powder was reconstituted with H 2 0 at 0.2 ml/mg of powdered vaccinia and 0.05 ml/mg powdered Factor VIII. Protocol Post Treatment Vaccinia Factor VIII . Titer Levels Vial # Treatment Temp. TCID -0 % of Control 1 Dry CHC1 3 20°C lO 5 75 2 Water saturated CHC1 3 20°C 0 94 3 Dry CHC1 3 37°C lO 4 ' 75 119 4 H„0 saturated CHC1 3 37°C 0 75 5 Dry CHC1- - 2% ethanol 20° 10 5 100 H-O saturated CHC1 3 - 2% ethanol 20' 100 Dry CHC1 3 - 5% ethanol 20' 10 4.75 119 H„0 saturated CHC1 3 - 5% ethanol 20% 96 CHC1 3 +H 2 0 2-phase 20° 0.3 10 CHC1 3 +H 2 0 2-phase 37° 0.3 11 H 2 0 only (control) 20° 5.5 10 100 Interpretation Chloroform saturated with water killed all of 5 5 . . . . the 10 " infectious vaccinia viruses in the lyophylized dry powder. Chloroform without dissolved water at or near the saturation point killed less than 10% of the infectious vaccinia virus and was therefore poorly effective in kill¬ ing the vaccinia virus. Increasing the temperature or ethanol content of the chloroform had little effect on virus killing if the chloroform or the chloroform alcohol were not also saturated with water. While water and chlo¬ roform together in a two-phase system was effective in virus killing, it also destroyed most of the Factor VIII activity. Factor VIII activity was maintained when the chloroform treatment was performed in a one-phase system whether or not the chloroform or chloroform/ethanol was saturated with water. It is concluded from Examples 1, 2, and 3 that lipid containing viruses contained in a dry protein powder can be killed by the lipid solvent, chloroform, if the chloroform is saturated with water. The water saturation point of 'chloroform can be increased by increasing the temperature or by adding ethanol. However, virus killing is effective as long as the dissolved water content ap¬ proaches the saturation point at the temperature or ethanol level used. It is further concluded that a blood product such as Factor VIII that is commonly prepared as a dry powder can be treated as a dry powder with water saturated chloroform without a significant loss of activity. ET

Claims: WE CLAIM: 1. A method of inactivating viruses that contain essential lipids in a dried protein carrier comprising contacting said viruses for an abbreviated period of time at a treatment temperature of about 4°C - 40°C with a treating composition consisting essentially of (a) a treating agent selected from one member of the group consisting of halogenated hydrocarbons and ethers and (b) water dissolved in said treating agent; and removing the treating agent from the protein carrier. 2. The method of Claim 1 wherein the abbreviated time is at least about 10 minutes. 3. The method of Claim 2 wherein the abbreviated time is from about 10 minutes to about 10 hours. 4. The method of Claim 1 wherein the dry protein carrier is a plasma protein for therapeutic or diagnostic - use. 5. The method of Claim 1 wherein the treating agent is chloroform. 6. The method of Claim 1 wherein the quantity of water dissolved in the treating agent is about 75-100% of the amount of water required to saturate the treating agent at the treatment temperature. 7. The method of Claim 1 wherein the treating agent is removed from the protein carrier by evaporation. 8. The method of Claim 6 wherein the water con¬ tent of the treating agent is adjusted by controlling the temperature of treatment. 9. The method of Claim 1 wherein the treating agent is a solution of chloroform and an alcohol formed by dissolving alcohol in the chloroform and then dissolving water in the chloroform-alcohol solution. 10. The method of Claim 9 wherein the treating agent is chloroform containing ethanol and the dissolved water content of the chloroform is adjusted to the amount necessary for 100% saturation of the chloroform-ethanol solution at the treatment temperature. 11. A method for inactivating a lipid virus in a dry blood- or plasma-derived protein product comprising adjusting the dissolved water content of chloroform in a treating composition consisting essentially of chloroform to about 100% of the amount required to sat¬ urate chloroform at a given treatment temperature; contacting the virus for an abbreviated period of time with said water-saturated chloroform treat¬ ing composition at a treatment temperature of from about 4°C to about 40°C; and removing the chloroform from the carrier. 12. The method of Claim 11 wherein the said virus is selected from at least one member of the group consisting of Hepatitis B virus (HBV) and non-A, non-B hepatitis virus (NANBH) . 13. The method of Claim 11 wherein the said virus is selected from at least one member of the lipid- containing groups consisting of herpesviruses, the delta agent, togaviruses, bunyaviruses, retroviruses, orthomyxo- viruses, paramyxoviruses, rhabdoviruses, poxviruses, hepad- naviruses, arenaviruses, and coronaviruses. 14. The method of Claim 11 wherein the said virus is selected from at least one member of the lipid-Gontaining group consisting of retroviruses. 15. A method of Claim 11 wherein the biologic activity of the blood- or plasma-derived protein product is substantially retained by the treatment. 16. A novel product from the process of Claim 11 comprising a blood or plasma protein derivative rendered noninfectious for lipid viruses wherein the inactivation was made by treatment with chloroform saturated 100% with water.

Inventors: FEINSTONE STEPHEN M, PURCELL ROBERT H, FEINSTONE, STEPHEN, M., PURCELL, ROBERT, H.
Applicants: FEINSTONE STEPHEN M, PURCELL ROBERT H, FEINSTONE, STEPHEN, M., PURCELL, ROBERT, H.
Application year: 1985
Main classification: A61K35
IPC codes: A61L2